You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 168 No. 12, June 23, 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Men's Health
 •Prostate Disease
 •Oncology
 •Radiation Therapy
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

COMMENTS AND OPINIONS
Prostate Cancer—Which Treatment to Choose?

Jarrod B. Adkison, MD; Mark A. Ritter, MD, PhD

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with interest the recent article by Merglen et al1 comparing prostate cancer treatments but have concerns regarding the analysis method used and conclusions reached. This retrospective study used the Geneva Cancer Registry and analyzed clinical outcomes of patients treated between 1989 and 1998 for prostate cancer. The authors concluded that radical prostatectomy patients experienced a lower rate of prostate cancer deaths than did those undergoing radiation therapy, observation, or hormonal therapy.

We believe that there are 3 significant limitations of this study by Merglen et al1 that challenge the authors' conclusions.

  1. The article fails to define its main end point, prostate cancer–specific death. Retrospectively determining the cause of death is a notoriously inaccurate undertaking. A common error, for example, would be to accept a death certificate that attributes death to prostate cancer without having accompanying documentation of metastatic disease.
  2. . . . [Full Text of this Article]


AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Short- and Long-term Mortality With Localized Prostate Cancer
Arnaud Merglen, Franz Schmidlin, Gerald Fioretta, Helena M. Verkooijen, Elisabetta Rapiti, Roberto Zanetti, Raymond Miralbell, and Christine Bouchardy
Arch Intern Med. 2007;167(18):1944-1950.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.